Summary
The therapeutic efficacy of fluvoxamine has been demonstrated in large numbers of patients participating in comparative double-blind placebo-controlled studies using imipramine as the active reference compound. Overall, patients treated with fluvoxamine for 4 to 6 weeks had significant amelioration of their depression compared with placebo-treated patients. More importantly, the response rate in patients with severe depression was greater than in patients with mild or moderate depression. However, several investigators have observed high placebo response rates, and in some studies there has been a similar response rate to imipramine and placebo treatment. While the high placebo response rate may have resulted from methodological problems, the issue does raise some questions that can only be resolved by further investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amin MM, Anath JV, Coleman BS, Darcourt G, Farkas T, et al. Fluvoxamine: antidpressant effect confirmed in a placebo controlled international study. Clinical Neuropharmacology 7 (Suppl. I): S312–S319, 1984
Bech P. A review of the antidepressant property of SSRI’s. In Advanced biological psychiatry, Vol. 17, pp. 58–69, Karger, Basel, 1988
Cassano GB, Conti L, Massimetti G, Mengali F, Wakelin JS, et al. Use of a standardized documentation system (BLIPS/BPD) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine and placebo. Psychopharmacology Bulletin 22: 52–58, 1986
Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology 90: 131–299, 1986
Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicentre study. Journal of Affective Disorders 18: 284–299, 1990
Feighner J, Boyer WF, Meredith CH, Hendrickson GG. A placebo-controlled inpatients comparison of fluvoxamine maleate and imipramine in major depression. International Clinical Psychopharmacology 4: 239–244, 1989
Ginestet D, et al. Etude de la fluoxetine dans le traitement des depressions endogènes et des mélancolics. International Clinical Psychopharmacology, in press, 1992
Itil T. A double-blind placebo controlled study of fluvoxamine and imipramine in out-patients with primary depression. British Journal of Clinical Pharmacology 15: 433S–438S, 1983
Norton K, Sireling LI, Bhat AV, Rao B, Paykel ES. A double-blind placebo controlled study of fluvoxamine, imipramine and placebo in depressed patients. Journal of Affective Disorders 7: 297–308, 1984
Ottevanger E. The efficacy of fluvoxamine in patients with severe depression. British Journal of Clinical Research 2: 125–132, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mendlewicz, J. Efficacy of Fluvoxamine in Severe Depression. Drugs 43 (Suppl 2), 32–39 (1992). https://doi.org/10.2165/00003495-199200432-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200432-00006